What if I’m diagnosed as an Alpha? Or a carrier?

There is a lot you can do.

What if I'm an Alpha?

What if I'm a carrier?

PROLASTIN-C—the leading alpha-1 augmentation therapy for over 20 years — is now improved.

Higher purity, shorter infusion time than Prolastin and FDA-approved labeling for prion removal.3

Find out more about PROLASTIN-C.

Prolastin Direct: one-stop enrollment, delivery & support

Prolastin Direct® Program secures insurance authorization, coordinates infusion services, ships PROLASTIN-C directly to the location of your choice and connects you to health management coordinators who are experienced Alpha-1 patients themselves.
Important Safety Information

Prolastin-C, Alpha1-Proteinase Inhibitor (Human) is for adults who have emphysema caused by inherited alpha1-antitrypsin deficiency. The effect of therapy with any alpha1-proteinase inhibitor (alpha1-PI) on pulmonary exacerbations and on the progression of emphysema in alpha1-antitrypsin deficiency has not been demonstrated in randomized, controlled clinical trials. PROLASTIN-C is not indicated as therapy for lung disease in patients in whom severe Alpha1-PI deficiency has not been established.

Prolastin-C may contain trace amounts of IgA. IgA deficient patients with antibodies against IgA should not receive Prolastin-C due to the risk of hypersensitivity.

The most common side effects during clinical trials with Prolastin-C were chills, a general feeling of being unwell, headache, rash, hot flush, and itching.

Prolastin-C is made from human plasma. Products made from human plasma may carry a risk of transmitting infectious agents, e.g., viruses, and, theoretically, the Creutzfeldt-Jakob disease (CJD) agent.

Please see accompanying Prolastin-C Full Prescribing Information for complete prescribing details.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.

  1. Wewers MD, Casolaro MA, Sellers SE, et al. Replacement therapy for alpha 1-antitrypsin deficiency associated with emphysema. N Engl J Med. 1987;316(17):1055-1062.
  2. Campos MA, Wanner A, Zhang G, Sandhaus RA. Trends in the diagnosis of symptomatic patients with alpha 1-antitrypsin deficiency between 1968 and 2003. Chest. 2005;128(3):1179-1186.
  3. PROLASTIN-C [package insert]. Grifols.